Vertex achieved another year of double-digit growth in 2024 thanks to its blockbuster cystic fibrosis (CF) therapies, with the newly approved next-generation drug, Alyftrek, adding to the momentum.
Approved in the US in late December, Alyftrek (vanzacaftor/tezacaftor/deutivacaftor) is a once-daily triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for CF patients six years and older who have at least one F508del
Key Takeaways
- Vertex achieved double-digit growth in 2024 thanks to its CF portfolio, with the next-generation Alyftrek recently approved
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?